McCrimmon, Rory J.
Catarig, Andrei-Mircea
Frias, Juan P.
Lausvig, Nanna L.
le Roux, Carel W.
Thielke, Desirée
Lingvay, Ildiko
Funding for this research was provided by:
Novo Nordisk
Article History
Received: 5 September 2019
Accepted: 6 November 2019
First Online: 2 January 2020
Duality of interest
: RJM reports grants from the Helmsley Trust, EU IMI, MRC, Diabetes UK and the JDRF during the conduct of the study and fees from Eli Lilly, Novo Nordisk and Sanofi outside the submitted work. JPF reports grants and personal fees from Novo Nordisk during the conduct of the study and grants and personal fees from Boehringer Ingelheim, BMS Eli Lilly, Merck, Pfizer and Sanofi outside the submitted work. CWlR reports grants and other support from the Health Research Board and the Science Foundation Ireland during the conduct of the study. Outside the submitted work, he reports grants, personal fees and other support from AnaBio, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GI Dynamics, Janssen, Johnson & Johnson, Keyron, Novo Nordisk and Sanofi. IL received research grants to her institution and consulting fees from Novo Nordisk during the conduct of the study. Outside the submitted work, she has received grants and/or personal fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, GI Dynamics, Intarcia, Mannkind, Merck, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi, TARGET PharmaSolutions and Valeritas. A-MC, NLL and DT are employees of Novo Nordisk A/S.